Membranous Nephropathy clinical trials

Explore recruiting membranous nephropathy clinical trials.

Recruiting membranous nephropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Membranous Nephropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy

Spain, Poland, Czechia, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Obinutuzumab induced decreases of PLA2Rab in MN: a pilot study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy

France

Phase III and phase IV (Integrated) EU CTIS Study details

Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy

France

Phase II and Phase III (Integrated) EU CTIS Study details

Membranous Nephropathy trials by city

Membranous Nephropathy in Toronto Membranous Nephropathy in Vancouver Membranous Nephropathy in Montreal Membranous Nephropathy in Calgary Membranous Nephropathy in Edmonton Membranous Nephropathy in Ottawa Membranous Nephropathy in Winnipeg Membranous Nephropathy in Quebec City Membranous Nephropathy in Hamilton Membranous Nephropathy in Kitchener Membranous Nephropathy in London Membranous Nephropathy in Halifax Membranous Nephropathy in New York Membranous Nephropathy in Los Angeles Membranous Nephropathy in Chicago Membranous Nephropathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease